1-20 of 45
Sebastian Grosicki, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

Maria Mateos, MD PhD, Maria Gavriatopoulou, Thierry Facon, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Roman Hajek, MD, Meletios A Dimopoulos, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Halyna Pylypenko, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Michele Cavo, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-138391
Published: 2020
Journal Articles

Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group

Grzegorz Charlinski, MDPhD, Agata Tyczyńska, MD, Jan M Zaucha, MD PhD, Adriana Czyz, MD, Jarosław Czyż, MDPhD, Dominik Dytfeld, MDPhD, Bartosz Malecki, MD, Lidia Gil, MDPhD, Szymon Fornagiel, MD, Sebastian Grosicki, MD PhD, Agnieszka Barchnicka, MD, Jadwiga Holojda, MD, Agnieszka Kolkowska, MD PhD, Iwona Hus, MD PhD, Grzegorz Helbig, MDPhD, Anna Kopinska, MD, Anna Masternak, MD, Dariusz Woszczyk, MDPhD, Miroslaw Markiewicz, MDPhD, Jaroslaw Piszcz, MDPhD, Janusz Kloczko, MDPhD, Lidia Usnarska-Zubkiewicz, MDPhD, Tomasz Wrobel, MD PhD, Pawel J. Robak, MDPhD, Tadeusz Robak, MDPhD, Anna Waszczuk-Gajda, MD, Grzegorz Basak, MD PhD, Artur Jurczyszyn, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-143003
Published: 2020
Journal Articles

Lenalidomide As Maintenance Therapy after R-CHOP Has No Protecting Effect for Central Nervous System Relapse in Frontline Treatment of Diffuse Large B-Cells Lymphoma. an Ancillary Studies of the Remarc Study

Sophie Bernard, Hervé Ghesquieres, MD PhD, Rene-Olivier Casasnovas, MD, Maria Gomes Da Silva, MD PhD, Pierre Feugier, MD PhD, Franck Morschhauser, MD PhD, Judith Trotman, FRACP, Richard Greil, MD, Dolores Caballero, MD PhD, Sebastian Grosicki, MD PhD, Koen Van Eygen, MD, Christiane Copie, MDPhD, Corinne Haioun, MDPhD, Catherine Thieblemont, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-136912
Published: 2020
Journal Articles

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Pier Luigi Zinzani, MD, Felipe Samaniego, MD, Wojciech Jurczak, MD PhD, Nilanjan Ghosh, MD PhD, Enrico Derenzini, MD PhD, James A Reeves, MD, Wanda Knopinska-Posluszny, MD PhD, Chan Yoon Cheah, MBBS, Tycel J. Phillips, MD, Ewa Lech-Marańda, MD PhD, Bruce D. Cheson, MD, Paolo F Caimi, MD, Sebastian Grosicki, MD PhD, Lori A. Leslie, MD, Julio C. Chavez, MD, Gustavo A. Fonseca, MD, Sunil Babu, Daniel J. Hodson, MDPhD, Spencer H. Shao, MD, John M. Burke, MD, Jeff P Sharman, MD, Jennie Y. Law, MD, John M. Pagel, MDPhD, Owen A. O'Connor, MD PhD, Hari P. Miskin, MSc, Peter Sportelli, BS, Michael S. Weiss, Nathan H Fowler, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34–35.
https://doi.org/10.1182/blood-2020-134851
Published: 2020
Journal Articles

Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa

Catherine Thieblemont, MD PhD, Maria Gomes da Silva, MD, Olivier Casasnovas, MD, Hervé Ghesquieres, MD PhD, Gandhi Laurent Damaj, MD PhD, Judith Trotman, FRACP, Pierre Feugier, MD PhD, Corinne Haioun, MDPhD, Richard Greil, MD, Dolores Caballero, MD PhD, Armando Lopez-Guillermo, Sebastian Grosicki, MD PhD, Koen Van Eygen, MD, Sylvia Snauwaert, MD, Ewa Lech-Marańda, MD PhD, Sonja Heibl, MD, John Catalano, MBBS, FRACP, FRCPA, Amos Cohen, MD, Anne Cairoli, MD, Philippe Gaulard, MD PhD, Franck Morschhauser, MD PhD, Herve Tilly, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-136511
Published: 2020
Journal Articles

Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial

Sara Bringhen, MD, Luděk Pour, MD, Reuben Benjamin, MBBS, FRCPath, PhD, Sebastian Grosicki, MD PhD, Chang-Ki Min, MD PhD, Danielle Leao Cordeiro De Farias, MDMSc,MBA, Alexander Vorog, MD, Richard J Labotka, MD, Bingxia Wang, PhD, Dasha Cherepanov, Lauren E. Cain, MHS, ScM, PhD, Sudhakar Manne, S. Vincent Rajkumar, MD, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-136293
Published: 2020
Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Shambavi Richard, MD, Ajai Chari, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, Hua Chang, PhD, Yosef Landesman, PhD, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Sebastian Grosicki, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-137154
Published: 2020
Journal Articles

An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Sebastian Grosicki, MD PhD, Genadi Iosava, MD, Mamia Zodelava, MD, Nikolay Tzvetkov, MD, Tadeusz Robak, MDPhD, Atanas Radinoff, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25.
https://doi.org/10.1182/blood-2020-136031
Published: 2020
Journal Articles

Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

Larysa Sanchez, MD, Xavier Leleu, MD, Jennifer Beaumont, Hailin Yu, Stacie Hudgens, MA, Holger W Auner, MD PhD, Hang Quach, MD, Sosana Delimpasi, MD, Ivan Spicka, MD PhD, Luděk Pour, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD PhD, Reuben Benjamin, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Levy, MD, Nizar J. Bahlis, MD, Thierry Facon, MD, Yi Chai, Xiwen Ma, Shijie Tang, Hoyee Leong, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-141319
Published: 2020
Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Holger W Auner, MD PhD, Maria Gavriatopoulou, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Meletios A Dimopoulos, Irina Kryachok, Professor, Halyna Pylypenko, MD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria Mateos, MD PhD, Michele Cavo, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137303
Published: 2020
Journal Articles

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Maria Mateos, MD PhD, Sundar Jagannath, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Maria Gavriatopoulou, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Reuben Benjamin, MD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Michele Cavo, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–52.
https://doi.org/10.1182/blood-2020-137574
Published: 2020
Journal Articles

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Robert M. Rifkin, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Sebastian Grosicki, MD PhD, Kihyun Kim, MD PhD, Francesco Di Raimondo, MD, Meletios A Dimopoulos, Katja Weisel, MD, Bertrand Arnulf, MD, Roman Hajek, MD, Vania T. M. Hungria, MD PhD, Andrew Spencer, Randy Davis, PhD, Antonio Riccio, PhD MBA, Chanbin Kim, Jodie Wilkes, Ruth Rutledge, Mala Talekar, MD, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Maria-Victoria Mateos, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 53–54.
https://doi.org/10.1182/blood-2020-139181
Published: 2020
Journal Articles

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Jean Jacques Kiladjian, MD PhD, Uwe Platzbecker, Jiri Mayer, MD, Árpád Illés, MD PhD, Witold Prejzner, MD PhD, Tomasz Wozny, MD PhD, Nikolay Tzvetkov, MD, Alessandro M. Vannucchi, MD, Ilya Kirgner, MD, Zsolt Nagy, MD PhD, Sebastian Grosicki, MD PhD, Åsa Rangert Derolf, MDPhD, Mihaela Lazaroiu, MD, Sung-Soo Yoon, MD PhD, Yeow Tee Goh, MBBS, Nikolas Von Bubnoff, Srdan Verstovsek, MD PhD, Barbara Jane Klencke, MD, Rafe Donahue, PhD, Ruben Mesa, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-135880
Published: 2020
Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Wojciech Jurczak, MD PhD, Ryan W. Jacobs, MD, Sebastian Grosicki, MD PhD, Krzysztof Giannopoulos, MD PhD, Tomasz Wrobel, MDPhD, Syed F. Zafar, MD, Jennifer L. Cultrera, MD, Suman Kambhampati, MD, Alexey Danilov, MD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD MPH, Javier Pinilla Ibarz, MD PhD, Jeff P Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, John M. Pagel, MDPhD, Kathryn S. Kolibaba, MD, Monika Dlugosz-Danecka, MD PhD, Nilanjan Ghosh, MD PhD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O'Connor, MD PhD, Michael S. Weiss, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–39.
https://doi.org/10.1182/blood-2020-134783
Published: 2020
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Hareth Nahi, MD PhD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Christoph Heuck, Xiang Qin, Dolly A. Parasrampuria, PhD, Ming Qi, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1865.
https://doi.org/10.1182/blood-2019-122765
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Maria-Victoria Mateos, MD PhD, Saad Z. Usmani, MD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Nizar Bahlis, MD, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Xiang Qin, Dolly A. Parasrampuria, PhD, Christoph Heuck, Ming Qi, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1906.
https://doi.org/10.1182/blood-2019-122501
Published: 2019
Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2945.
https://doi.org/10.1182/blood-2019-123836
Published: 2019
Journal Articles

Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Moshe Mittelman, MD, Uwe Platzbecker, MD, Boris Afanasyev, MD PhD, Sebastian Grosicki, MD PhD, Maria Socorro O Portella, MD MBA, Zewen Zhu, Dominik Selleslag, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3740.
https://doi.org/10.1182/blood-2019-130309
Published: 2019
Journal Articles

High Activity of Cladribine (2-CdA) Combined with Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Azacitidine Failure

Kamil Wisniewski, Krzysztof Madry, Sebastian Grosicki, MD PhD, Piotr Małecki, Bartosz Pula, Marzena Watek, Ewa Lech-Maranda, MD PhD, Joanna Gora Tybor, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1360.
https://doi.org/10.1182/blood-2019-123843
Published: 2019
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Maria-Victoria Mateos, Michele Cavo, Joan Bladé, MD PhD, Meletios A. Dimopoulos, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, MD PhD, Zsolt Nagy, MD PhD, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, MD FRCP, FRCPath, Maria Krevvata, PhD, Jianping Wang, Anupa Kudva, MD, Jon Ukropec, PhD, Susan Wroblewski, PhD, Rachel Kobos, MD, Jesús San-Miguel
Journal: Blood
Blood (2019) 134 (Supplement_1): 859.
https://doi.org/10.1182/blood-2019-123401
Published: 2019